跳至主要内容
临床试验/ACTRN12616000895482
ACTRN12616000895482招募中4 期

Impact of continuous antiplatelet therapy versus temporary interruption of antiplatelet therapy on immediate and clinically significant delayed bleeding after colonoscopic polypectomy: a randomised controlled trial

The Alfred0 个研究点目标入组 992 人开始时间: 2016年7月7日最近更新:
适应症

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
992

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Prevention
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • *Any patient aged >18 years scheduled for routine colonoscopy who is
  • * On single agent antiplatelet therapy: clopidogrel or prasugrel or ticagrelor
  • * On dual antiplatelet agent: aspirin and clopidogrel or prasugrel or ticagrelor

排除标准

  • One or more of the following criteria precludes trial eligibility
  • Liver cirrhosis
  • * Chronic renal impairment (eGFR less than or equal to 30)
  • * History of a bleeding diathesis
  • * Thrombocytopenia of any cause (Platelet count less than or equal to 90)
  • * Other concurrent anticoagulation/antiplatelet agents
  • * Percutaneous coronary intervention
  • - with bare metal stent within the last 30 days
  • - with drug eluding stent within the last 12 months
  • *Acute coronary syndrome within the last 90 days
  • * Any other concern by treating physician(s)
  • * Inability to provide informed consent

研究者

发起方
The Alfred

相似试验